CRA-026440 is a potent and selective inhibitor of the sodium-calcium exchanger (NCX) in its reverse mode. It is primarily utilized in pharmacological and cardiovascular research to investigate cardioprotective effects, particularly in models of myocardial ischemia-reperfusion injury. By blocking calcium influx into cardiomyocytes, it reduces cellular damage and necrosis associated with heart conditions like acute myocardial infarction. Preclinical studies have demonstrated its ability to preserve cardiac function and limit infarct size. Further research is exploring its pharmacokinetics, safety profile, and potential as a therapeutic agent for cardiovascular diseases, including possible combinations with other cardioprotective drugs.